MBX 10-Q: SEC filing
MBX Biosciences
Filed with the SEC on · accession 0001193125-26-453583
MBX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +5.3% by the first close after the filing.
Summary of the filing
MBX Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing an at-the-market (ATM) offering program and equity incentive plan activity.
Key details
How MBX stock reacted
Close before
$51.35
Nov 6, 2026
First close after
+5.28%
$54.06
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MBX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MBX?
Click hereFrequently asked questions
What did MBX file with the SEC on Nov 9, 2026?
MBX filed a 10-Q (SEC filing). MBX Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing an at-the-market (ATM) offering program and equity incentive plan activity.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did MBX stock react to this filing?
MBX closed at $51.35 before the filing and $54.06 on Nov 9, 2026 (+5.28%).
Other MBX SEC filings
- SCHEDULE 13G/A · SEC filingNov 5, 2026
- 8-K · Board changeOct 22, 2026
- 8-K · Fda approvalAug 27, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13D/A · SEC filingAug 10, 2026
- SCHEDULE 13D/A · SEC filingAug 10, 2026
- 8-K · SEC filingAug 6, 2026
- 10-Q · SEC filingAug 6, 2026
- 8-K · Ceo changeJul 13, 2026
- 8-K · Fda approvalJun 12, 2026
Get alerts when MBX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days